DIAGNOS Provides Financing Updates
Momentum Public Relations
Press Release: June 29 2018
DIAGNOS Inc. (“DIAGNOS” or “the Corporation”) (TSX VENTURE:ADK) (OTCQB:DGNOF), a leader in early detection of critical health issues through the use of its FLAIREplatform based on Artificial Intelligence (AI), provides updates on financing activities previously announced on June 14, 2018.
Private placement of units
The Corporation announces a new closing date of July 4th, 2018 in connection with the private placement of units (each a “Unit”) for gross proceeds of up to $1,200,000. Each Unit consists of:
- One Secured, Convertible and Redeemable Debenture (“Debenture”), 3-year term, 10% annual interest, principal of $50,000 per Debenture, and
- 200,000 stock warrants (each a “Stock warrant”) entitling the holder to purchase one common share (“Share”) per Warrant at a price of $0.15 per Share, for a period of 18 months from the date of issuance of the Stock warrant.
Private placement – shares
The Corporation announces the cancellation of , 800,000 units (each a “Share-unit”), for gross proceeds of $60,000, in connection with the $120,000 private placement of common shares and stock warrants. Each Share-unit consists of;
- one common share (“Share”), and
- one stock warrant (“Warrant”) entitling the holder to purchase one Share per Warrant at a price of $0.10 per Share, for a period of 18 months from the date of issuance of the Warrant.
The cancellation is subject to receipt of all required regulatory approvals, including the approval of the TSX Venture Exchange, as well as the execution of formal documentation.
All monies quoted in this press release shall be stated and paid in lawful money of Canada.
About DIAGNOS
DIAGNOS is a publicly-traded Canadian corporation with a mission of early detection of critical health issues through the use of its Artificial Intelligence (“AI”) tool CARA (Computer Assisted Retina Analysis). CARA is a tele-ophthalmology platform that integrates with existing equipment (hardware and software) and processes at the point of care (“POC”). CARA’s Artificial Intelligence image enhancement algorithms make standard retinal images sharper, clearer and easier to read. CARA is accessible securely over the internet, and is compatible with all recognized image formats and brands of fundus cameras, and is EMR compatible. CARA is a cost-effective tool for screening large numbers of patients in real-time and has been cleared for commercialization by several regulatory authorities such as Health Canada, the U.S. Food and Drug Administration and the European Union.
Additional information about DIAGNOS is available at www.diagnos.com and www.sedar.com.
For further information, please contact:
Mr. André Larente, President | Mr. Josh Falle | ||
DIAGNOS Inc. | Momentum PR | ||
Tel: 450-678-8882 ext. 224 | Tel: 514-416-4656 | ||
alarente@diagnos.ca | josh@momentumpr.com |
This news release contains forward-looking information. There can be no assurance that forward-looking information will prove to be accurate, as actual results and future events could differ materially from those anticipated in these statements. DIAGNOS disclaims any intention or obligation to publicly update or revise any forward-looking information, whether as a result of new information, future events or otherwise. The forward-looking information contained in this news release is expressly qualified by this cautionary statement.
Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.
- Published in Diagnos
Tetra Bio-Pharma’s Evidence-Based Business Model Confirmed
Momentum Public Relations
Press Release: June 29 2018
Tetra Bio-Pharma Inc.(TBP:V), a leader in cannabinoid-based drug discovery and development, today announced that the amendment of the Prescription Drug List (PDL) to include phyto-cannabinoids supports its evidence-based business model. Since early 2016 Tetra’s product development and commercialization strategy followed the exact same pathway as that used in the development of prescription drugs, namely rigorous, independently validated scientific evidence. As a biopharmaceutical company, Tetra’s orientation is to bring cannabis and cannabinoid-based products to market that meet the regulatory quality, safety and efficacy requirements for prescription medications.
Health Canada recently issued a Notice of Intent to Amend the PDL to add phytocannabinoids produced by, or found in, the cannabis plant and substances that are duplicates of such phytocannabinoids. In 2017, Tetra completed a major safety, pharmacokinetic and pharmacodynamic study in healthy human subjects that allowed Tetra to collect significant data to support its marketing applications. A similar clinical development program was launched with cannabis oils in preparation for the upcoming post-legalization market. The combination of safety, pharmacokinetic and efficacy data allows Tetra to bring products to market under the proposed new regulatory framework. Tetra Bio-Pharma is one of a few cannabinoid based companies that is committed to providing much needed clinical data for both its pharmaceutical and natural health products.
Over the coming months Tetra Bio-Pharma will deliver its findings in a series of presentations and scientific articles that will be published in 2018 to share the clinical data of both the inhalation and oral clinical development programs with the medical community, beginning with the July 4, 2018 International Cannabinoid Research Society Meeting in the Netherlands where Dr. Maria-Fernanda Arboleda, MD, will present the results of the above clinical trial. http://www.icrs.co/
Update on North Bud Farms Inc.
Tetra Bio-Pharma has agreed to provide an extension to North Bud Farms Inc. with regards to the receipt of North Bud’s preliminary and final prospectus. As one of the closing conditions to the sale these documents must now be submitted by July 31, 2018.
About Tetra Bio-Pharma
Tetra Bio-Pharma (TSX-V:TBP) (OTCQB:TBPMF) is a biopharmaceutical leader in cannabinoid-based drug discovery and development with a Health Canada approved, and FDA reviewed, clinical program aimed at bringing novel prescription drugs and treatments to patients and their healthcare providers. The Company has several subsidiaries engaged in the development of an advanced and growing pipeline of Bio Pharmaceuticals, Natural Health and Veterinary Products containing cannabis and other medicinal plant-based elements. With patients at the core of what we do, Tetra Bio-Pharma is focused on providing rigorous scientific validation and safety data required for inclusion into the existing bio pharma industry by regulators, physicians and insurance companies.
More information at: www.tetrabiopharma.com
Source: Tetra Bio-Pharma
Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.
- Published in Tetra Bio Pharma
Stelmine completes the first $496 000 tranche of a private placement with investors including institutional funds
Momentum Public Relations
Press Release: June 29 2018
Stelmine Canada Ltd.(STH:V), a junior mining exploration company which concentrates its activities in the Province of Québec announced today the closing of the first tranche of a non-brokered private placement concluded with investors including institutional funds.
The first tranche of the private placement (the “Placement”) consists in the issuance of 2 480 000 units (the “Units”) at a price of $0.20 per unit, for placement of $496,000; each Unit is composed of one (1) common share of Stelmine (“Share”) and one half (1/2) common share purchase warrant, each warrant entitling its holder to subscribe to one (1) Share at a price of $0.30 per Share during an 18-month period.
The following funds participated in the first tranche of the Placement: Capital croissance PME II S.E.C. (CCPME), Société de développement de la Baie James (SDBJ), as well as the Fonds de solidarité FTQ and SIDEX, these last two, in an amount of $100,000 each through FIELD-ACTION 2018, an initiative designed to encourage junior mining companies to perform their fieldwork in Québec while at the same time supporting their working capital.
“I am very pleased that these important institutions, which proceeded to a first investment in 2017, have renewed their confidence in Stelmine’s projects”, said Isabelle Proulx, the Company’s President and CEO. “This financing will allow our company to continue during the summer of 2018 the work program initiated in 2017.”
An insider of the Company participated to this Placement for proceeds of $5,000. This insider subscribed to the Units under the same terms as the other investors. The participation of this insider is exempt from the formal valuation and shareholder approval requirements as per Sections 5.5(a) and 5.7(1)(a) of Regulation 61-101 respecting Protection of Minority Holders in Special Transactions. The exemption is based on the fact that the market value of such participation or the consideration paid by such insider does not exceed 25% of the market value of the Company.
All securities issued in connection with this Placement are subject to a hold period of four months and one day. The Placement is subject to the approval of the TSX Venture Exchange. Stelmine has not filed a material change report in the 21 days preceding the Placement.
The proceeds of this Placement will be used for the Company’s operating costs and working capital.
About Stelmine
Stelmine is a junior mining exploration company and its activities are located in the Province of Québec. Stelmine holds 994 claims spanning 517 km2 on the eastern part of the Opinaca metasedimentary basin, which contains zones with a high potential for gold deposit discovery in geological contexts similar to the one leading to discovery of the Éléonore Mine. Its capital stock consists of 26,160,645 issued and outstanding shares for a current market capitalization of $5,2 million.
About CCPME
CCPME is a fund jointly set up by the Caisse de dépôt et placement du Québec and by Capital Régional et Coopératif Desjardins for the purpose of supporting the economic development of Québec businesses and encouraging their growth. The Placement will be made by CCPME, for which Gestion Desjardins Capital Inc. acts as manager.
About SDBJ
Created in 1971 by the James Bay Region Development Act, the SDBJ’s mission is to promote the James Bay territory’s economic development and the development and use of its natural resources, other than hydroelectric resources, which are Hydro-Québec’s responsibility, from a sustainable development perspective. It can generate, support and participate in projects for these purposes. www.sdbj.gouv.qc.ca
About SIDEX
SIDEX is an initiative of the Québec government and the Fonds de solidarité FTQ whose mission is to invest in companies engaged in mineral exploration in Québec in order to diversify the province’s mineral base, promote innovation and new entrepreneurs.
About Fonds de solidarité FTQ
The Fonds de solidarité FTQ is a capital development fund that channels the savings of Quebecers into investments. With $13.7 billion in net assets as at November 30, 2017, the Fonds has helped create and maintain over 186,440 jobs. The Fonds has more than 2,700 partner companies and over 645,000 shareholder-savers.
Forward-Looking Statements
The statements set forth in this press release, which describes Stelmine’s objectives, projections, estimates, expectations or forecasts, may constitute forward-looking statements within the meaning of security legislation. Positive or negative verbs such as “believe”, “can”, “shall”, “intend”, “expect”, “estimate”, “assume” and other related expressions are used to identify such statements. Stelmine wishes to state that, by their very nature, forward-looking statements involve risks and uncertainties such that its results, or the measures it adopts, could differ materially from those indicated or underlying these statements or could have an impact on the degree of realization of a particular projection. Major factors that may lead to a material difference between Stelmine’s actual results and the projections or expectations set forth in the forward-looking statement include the risk that the Company does not complete the Placement as anticipated, and such other risks as described in detail from time to time in the reports filed by Stelmine with security authorities in Canada. Unless otherwise required by applicable securities laws, Stelmine disclaims any intention or obligation to update or revise any forward-looking statements, whether as a result of the new information, future events or otherwise. The forward-looking information in this release is based on information available as of the date of this release.
The TSX Venture Exchange has not reviewed and does not accept responsibility for the adequacy or accuracy of this release.
For more information :
Isabelle Proulx President and CEO |
Christian Guilbaud Director |
418-626-6333 info@stelmine.com |
514-813-7862 |
Stelmine.com |
- Published in Stelmine Canada
Stelmine initiates a new exploration campaign on its Courcy flagship property
Momentum Public Relations
Press Release: June 21 2018
Stelmine Canada.(STH:V). Stelmine announces the start of its summer 2018 exploration program on the Courcy flagship property. The gold property is located in the eastern segment of the Opinaca sub-province near the Québec/Labrador border.
2018 Program
Courcy property
The main objective of this campaign is to circumscribe and expand all zones containing gold mineralization and positioning drill collars for a drilling campaign to be initiated during the fall of 2018. Based on the results obtained from previous field work completed in 2017, the exploration work will include:
- detailed geological and structural mapping;
- rock sampling (grab and channel), and overburden stripping on 17 priority zones containing gold mineralization distributed throughout the property.
Other properties
Stelmine will devote 10 days to each the Trieste and Joubert properties, exploring (mapping and sampling) key areas where gold mineralization was discovered in 2017. The largely unexplored Mercator property will undergo regional exploration which is expected to last several days.
2017 Program
More than 1.2M$ was spent on a summer exploration campaign that was successful in discovering new potential Au-rich targets on the eastern Courcy property. Geological mapping combined with the reinterpretation of previous geophysical VTEM, THEM and MaxMin surveys allowed the definition of a new geological and structural framework related to gold mineralization. Over 2,000 m2 of overburden was stripped from 13 new mineralized sites. A total of 751 rock samples, including 265 channel samples having a total length of 265 m were collected from outcrops, ancient and new stripped zones.
To date, the Courcy North and South zones are deemed the most prospective for gold. The best results for the North zone varies from 0.31 to 8.38 g/t Au, with an average concentration of 1.29 g/t Au if we merge Stelmine and SOQUEM’s previous data. Significant channel sample results yielded 1.05 g/t Au on 8.39 m, 1.79 g/t on 4.10 m and 1.58 g/t on 4.20 m.
In the South Zone, several showings displayed visible gold and elevated Au concentrations in grab samples (ex: 167 g/t, 33 g/t, 24.8 g/t and 4.8 g/t). A compilation of values > 0.3 g/t obtained by Stelmine and SOQUEM produced an average of 3.65 g/t Au.
2006 Program
SOQUEM completed a drilling campaign, including 772 m of core material distributed in eight diamond drill holes and producing the following results: 4.27 g/t Au on 42 m (including 12.15 g/t Au on 13.5 m; drill hole no. 8), 0.94 g/t Au on 10.50 m (drill hole no. 4) and 0.4 g/t Au on 15 m (drill hole no. 2).
Stelmine’s President and CEO, Isabelle Proulx declares “Our exploration strategy on the Courcy property is specifically designed to focus on the most important gold-bearing targets throughout the property and will ultimately lead to a drilling campaign. The completion of our second year of field work will strongly benefit from our geological, geophysical and geochemical knowledge acquired from last year. In targeting the eastern segment of the Opinaca subprovince, Stelmine generated a renewed interest from the mining industry. Our results are now being closely monitored as we further explore the mining potential of this newly investigated mining sector”.
The Courcy property is located 100 km west of the city of Fermont, Québec. The property consists of 393 claims covering 206 km2 and is 100 % owned by Stelmine. Stelmine’s base camp is located on lac Couteau. A team comprising two senior geologists, two junior geologists, two technicians accompanied by a foreman and a cook is presently on site and carrying out work.
The technical contents of this release were approved by Michel Boily, PhD, geo; a Qualified Person (QP) as defined by National Instrument 43-101.
Follow us on www.Stelmine.com and on our Facebook page (Stelmine Canada) where we uploaded pictures of the Courcy project.
About Stelmine
Stelmine is a junior mining exploration company which concentrates its activities in the Province of Québec. Stelmine holds 994 claims spanning 517 km2 on the eastern part of the Opinaca metasedimentary basin, which contains zones with a high potential for gold deposit discovery in geological contexts similar to the one leading to discovery of the Éléonore Mine. Its capital stock consists of 23,680,645 issued and outstanding shares for a current market capitalization of $4.7 million.
Forward-looking statements
The statements set forth in this press release, which describes Stelmine’s objectives, projections, estimates, expectations or forecasts, may constitute forward-looking statements within the meaning of security legislation. Positive or negative verbs such as “believe”, “can”, “shall”, “intend”, “expect”, “estimate”, “assume” and other related expressions are used to identify such statements. Stelmine wishes to state that, by their very nature, forward-looking statements involve risks and uncertainties such that its results, or the measures it adopts, could differ materially from those indicated or underlying these statements or could have an impact on the degree of realization of a particular projection. Major factors that may lead to a material difference between Stelmine’s actual results and the projections or expectations set forth in the forward-looking statement include the risk that the Company does not complete the Placement as anticipated, and such other risks as described in detail from time to time in the reports filed by Stelmine with security authorities in Canada. Unless otherwise required by applicable securities laws, Stelmine disclaims any intention or obligation to update or revise any forward-looking statements, whether as a result of the new information, future events or otherwise. The forward-looking information in this release is based on information available as of the date of this release.
The TSX Venture Exchange has not reviewed and does not accept responsibility for the adequacy or accuracy of this release.
For more information : | |
Isabelle Proulx | Christian Guilbaud |
President and CEO | Business Development |
418-626-6333 | 514-813-7862 |
info@stelmine.com | |
Stelmine.com |
- Published in Stelmine Canada
Continued demand seen for battery metals
Momentum Public Relations
Blog: June 20 2018
Bloomberg New Energy Finance predicts that by 2040 55% of all new car sales and 33% of the global fleet will be electric.
Wheaton Precious Metals and Cobalt 27 sign streaming agreements for Voisey’s Bay cobalt
Continued demand seen for battery metals
Sometimes paradigm shifts begin to take place without you really noticing them. Last week when I was driving between Montreal and Ottawa I saw two electric vehicles and one of them was doing more than 120. When I visited a building on business one day I noticed that there were four electric vehicle charging stations. Earlier on in the year I noticed that a raft of recharging stations was being installed at the Fairview Mall in Pointe Claire.
Spotting two electric cars driving to Ottawa doesn’t amount to very much in the grand scheme of things except to say that I go to Ottawa fairly frequently and have never before seen a single electric vehicle on the 417. As a symbol of things to come those two EVs qualify as a harbringer of change.
Bloomberg New Energy Finance has predicted in a recent report that by 2040, 55% of all new car sales and 33% of the global fleet will be electric. It also predicts sales of electric vehicles increasing from a record 1.1 million worldwide in 2017, to 11 million in 2025 and then surging to 30 million by 2030 as they become cheaper to make than internal combustion engine vehicles. That 55% of the market by 2040, breaks down to 60 million vehicles.
In many cases air pollution is driving the shift from gas to electric, especially in China where Bloomberg forecasts the country will take a leadership role in EV production and purchase. By 2025 Bloomberg believes China will account for almost 50% of the EVs purchased globally, declining to 39% annually by 2030 as global demand picks up.
The report notes that the increase in EV demand will create a longterm demand for battery metals. These include: lithium; cobalt, graphite, manganese and nickel. Curiously, the report did not figure into account the rising demand for battery metals generated by utility scale battery farms that store electricity generated by wind, wave and solar energy.
Bloomberg paints a rosy picture for longterm battery metal demand and they are not alone. Perhaps the most interesting development in the battery market can be seen in the development of a company, Cobalt 27 Capital Corp., whose corporate strategy is based on stockpiling physical cobalt and creating royalty stream agreements with cobalt mining companies. Cobalt 27 has royalty stream agreements with four producing cobalt miners and eight exploration stage cobalt companies.
On June 11, 2018 Cobalt 27 and Wheaton Precious Metals signed separate royalty streaming agreements with Brazilian mining giant Vale to acquire a majority of the cobalt produced at Voisey’s Bay. Royalty streaming agreements were originally developed in the gold mining industry as a way for a major company to secure gold in exchange for financing gold exploration and in some cases both exploration and mine development.
Vale will use the capital raised, a combined US$690 million to finance its expansion at Voisey’s Bay, a project which had before this been put on hold. In the February 21st edition of Resource World, Peter Kennedy reports on a BMO Capital Markets report on battery metals that questions whether or not cobalt will retain its key position as a battery metal.
The thinking goes like this: The majority of the world’s cobalt is produced in the Democratic Republic of Congo, Kennedy quotes from the report, “No purchasing manager wants to be so reliant on the supply of a critical raw material from a single supply source, particularly one with a poor human rights track record and the threat of political instability.”
While this state of affairs and Tesla’s known desire for a North American supply change have jointly fueled the rush to explore and develop North American cobalt resources it may also be driving battery manufacturers to develop a lithium-ion rechargeable battery containing much less cobalt. In the near term BMO wouldn’t be surprised to see a doubling in cobalt prices. The report also notes that cobalt demand has grown from 40,000 tonnes in 2000 and is predicted to rise above 100,000 tonnes for the first time in 2018.
Any active investor is probably wondering, if they haven’t already decided, just what the best play will turn out to be in battery metals. Cobalt is like silver, it is usually found with other metals in the case of Voisey’s Bay, that metal is nickel. If you decided to bet on existing battery technology then a company like Cobalt 27 may very well be your ticket.
If you want to temper that exposure with gold and silver then Wheaton Precious Metals may be the company you are looking for.
On the other hand you may want to consider a company like SRG Graphite, (TSXV: SRG) which traded in the C$1.20 range on June 18th. SRG has an advantage over other battery metal stocks because it is in the process of exploring and developing deposits of three of the most important battery metals, graphite, nickel and cobalt.
While you can easily understand the value of cobalt and nickel in EV batteries graphite is a bit of a dark horse that is going to sooner or later win the Triple Crown because of what can be done with.
Well known as an industrial lubricant or the lead in lead pencils, graphite is an amazing material that will become increasingly important as it is used to develop new technologies.
British scientists have developed a graphite based coating that when applied to a building can be used to generate enough solar power to provide all the electricity the building needs to function, lights, heating and cooling.
Not being content with just being a power source the graphite coating can also change colours on demand. Because of its nature as a highly conductive material graphite is also at the foreground in nanotechnology. Simply put graphite is the metal of the future.
SRG has a 100% owned property in the Republic of Guinea, West Africa where it is developing two separate deposits, the first is the Lola graphite deposit, which at 8.7 km long and on average 370 meters wide is one of the largest in the world. A recent mineral resource estimate on the Lola project shows a measured and indicated resource of 12.2 million tonnes grading 5.6% graphite and an inferred resource 2.1 million tonnes grading 6.1%.
The second is the company’s nickel/cobalt/scandium deposit, Gogota, is located on the same mining claim as Lola. A recent NI 43-101 shows that Gogota has an inferred resource of 44.9 tonnes of mineralized material grading 1.28% nickel for 573,040 tonnes of contained nickel, 0.13% cobalt for 59,560 tonnes of contained cobalt and 29.4 grams per tonne of scandium for 1.17 tonnes contained scandium.
For an investor, buying SRG really provides the opportunity to hedge your bets in the battery metals market. If longterm demand for cobalt weakens because of new battery chemistries that require less cobalt, the graphite and nickel deposits are there to pick up the slack. And then there is the unknown role that graphite will play as a supermaterial in the future to consider.
This blog does not constitute investment advice. Investors should perform their own due diligence when buying shares in a company. In the interests of transparency, SRG Graphite is a client of Momentum PR.
- Published in Blog
Tetra Bio-Pharma Adds a New Leader for its Commercial Operations
Momentum Public Relations
Press Release: June 19 2018
Tetra Bio-Pharma Inc., a leader in cannabinoid-based drug discovery and development (TSX VENTURE:TBP) (OTCQB:TBPMF), is pleased to announce that Mr. Richard Giguere has been hired as Executive Vice-President, Commercial Operations. He will be responsible for the commercial sales and operations of Tetra Natural Health and Tetra Veterinary Health.
Richard has more than 20 years’ experience in sales and marketing in the pharmaceutical industry from coast to coast. During his career, he has held various business development, management and negotiation positions and launched several new products on the Canadian market. He has worked for various pharmaceutical companies in sectors such as generics, branded products and medical devices. He has also worked with OTC, natural products and original medications. Richard is recognized for his deep ethical sense, respect of others and talent for developing long-term business relationships through flexibility and efficiency. In the past 10 years, he was also a board member at the companies for which he worked.
“We’re very proud to add Richard Giguere to our senior management team. His vast experience in the sales and marketing of OTC, natural health products and original medications in the pharmaceutical industry across Canada will help drive the execution of our corporate strategy for our Tetra Natural Health and Tetra Veterinary Health divisions,” says Guy Chamberland, Interim Chief Executive Officer of Tetra Bio-Pharma.
Richard Giguere’s arrival is perfectly aligned with Tetra Bio-Pharma’s decision to restructure its corporation by commercial markets. While Tetra Bio-Pharma will be dedicated to pharmaceutical development and commercialization of cannabinoid-based prescription drugs and treatments, Tetra Natural Health will develop and sell cannabinoid-based OTC (self-care) products to leverage the post-legalization market and Tetra Veterinary Health will focus on commercialization of cannabinoid-based products for the pet product market.
“I am honored to be able to play an active role in growing both the Tetra Natural Health and Tetra Veterinary Health divisions,” says Richard Giguere, EVP, Commercial Operations. “Tetra has a sound business model, and there are significant opportunities for us to grow our two commercial divisions. I am committed to making the best business and commercial decisions to accelerate the development of these huge potential markets for our cannabinoid-based products.”
As a result of this senior management change, Anne-Sophie Courtois left the corporation thereby terminating her role as Vice President, Marketing and Communications.
About Tetra Bio-Pharma:
Tetra Bio-Pharma (TSX-V: TBP) (OTCQB: TBPMF) is a biopharmaceutical leader in cannabinoid-based drug discovery and development with a Health Canada approved, and FDA reviewed, clinical program aimed at bringing novel prescription drugs and treatments to patients and their healthcare providers. The Company has several subsidiaries engaged in the development of an advanced and growing pipeline of Bio Pharmaceuticals, Natural Health and Veterinary Products containing cannabis and other medicinal plant-based elements. With patients at the core of what we do, Tetra Bio-Pharma is focused on providing rigorous scientific validation and safety data required for inclusion into the existing bio pharma industry by regulators, physicians and insurance companies. For more information visit: www.tetrabiopharma.com
More information at: www.tetrabiopharma.com
Source: Tetra Bio-Pharma
Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.
Forward-looking statements
Some statements in this release may contain forward-looking information. All statements, other than of historical fact, that address activities, events or developments that the Company believes, expects or anticipates will or may occur in the future (including, without limitation, statements regarding potential acquisitions and financings) are forward-looking statements. Forward-looking statements are generally identifiable by use of the words “may”, “will”, “should”, “continue”, “expect”, “anticipate”, “estimate”, “believe”, “intend”, “plan” or “project” or the negative of these words or other variations on these words or comparable terminology. Forward-looking statements are subject to a number of risks and uncertainties, many of which are beyond the Company’s ability to control or predict, that may cause the actual results of the Company to differ materially from those discussed in the forward-looking statements. Factors that could cause actual results or events to differ materially from current expectations include, among other things, without limitation, the inability of the Company to obtain sufficient financing to execute the Company’s business plan; competition; regulation and anticipated and unanticipated costs and delays, the success of the Company’s research and development strategies, the applicability of the discoveries made therein, the successful and timely completion and uncertainties related to the regulatory process, the timing of clinical trials, the timing and outcomes of regulatory or intellectual property decisions and other risks disclosed in the Company’s public disclosure record on file with the relevant securities regulatory authorities. Although the Company has attempted to identify important factors that could cause actual results or events to differ materially from those described in forward-looking statements, there may be other factors that cause results or events not to be as anticipated, estimated or intended. Readers should not place undue reliance on forward-looking statements. While no definitive documentation has yet been signed by the parties and there is no certainty that such documentation will be signed The forward-looking statements included in this news release are made as of the date of this news release and the Company does not undertake an obligation to publicly update such forward-looking statements to reflect new information, subsequent events or otherwise unless required by applicable securities legislation.
More information at: www.tetrabiopharma.com
For further information, please contact Tetra Bio-Pharma Inc.
Guy Chamberland, Interim Chief Executive Officer
Guy@tetrabiopharma.com
For investors information, please contact:
investors@tetrabiopharma.com
(438) 504-5784
For media information, please contact:
Daniel Granger
Daniel.granger@acjcommunication.com
ACJ Communication
O: 1 514 840 7990 M: 1 514 232 1556
- Published in Tetra Bio Pharma
SRG Graphite increases resource estimate at Lola by 54%
Momentum Public Relations
Press Release: June 18 2018
SRG Graphite Inc. has provided an updated mineral resource estimate for its 100-per-cent-owned Lola graphite deposit located in the Republic of Guinea. The 2018 mineral resource estimate represents an increase of 54 per cent of in situ graphitic carbon (Cg) at a 3-per-cent cut-off grade since the publication of the maiden resource. In preparation for the next phase of development of the project, several boreholes were completed to increase measured and indicated resources from inferred resources. As such, measured and indicated resources increased from 224,118 tonnes to 676,900 tonnes of Cg content at a 3-per-cent cut-off grade, an increase of 201 per cent.
The 2018 Mineral Resource Estimate, prepared by Montreal-based Met-Chem, a division of DRA Americas Inc. (“Met-Chem/DRA”), includes a pit-constrained measured and indicated resource of 12.2 million tonnes (“Mt”) grading 5.6% Cg and an inferred resource of 2.1 Mt grading 6.1% Cg, using a cut-off grade of 3.0% Cg. Effective date of the estimate is June 14, 2018.
The 2018 Mineral Resource Estimate replaces the maiden mineral resource estimate which was reported by SRG on December 22, 2017, and subsequently included in a Technical Report completed by Met-Chem/DRA with an effective date of September 30, 2017. A NI 43-101 Technical Report will be filed on SEDAR within 45 days of this news release providing the details of this resource update. Figure 1 provides a map of the current drilling program. Completed boreholes, assay results pending and boreholes to be completed can be viewed on the map.
Resource Summary
The mineral resources are based on 395 boreholes for 12,086 meters (“m”) drilled up to April 4, 2018. Since that time, an additional 162 diamond drill holes have been completed, for approximately 5,686 additional meters for a total of 17,954 meters. Assay results for these additional holes are pending. Drilling onsite is ongoing and an additional 3,000 meters of drilling are scheduled to take place in the second half of 2018.
The updated resource is established for the oxide profile of the deposit, from surface to a depth ranging between 20 and 50 meters, with an average thickness of 32 meters. The mineralization continues at depth within the fresh rock material, but drilling is stopped once fresh rock is reached. The area for the resources covers approximately 33% of the deposit’s 3.2-square-kilometer surface area.
The estimate was prepared using a block model constrained with 3D wireframes of the principal mineralized domains. Values for graphitic carbon were interpolated using Ordinary Kriging (OK) interpolation methodologies on 10 * 10 * 2m blocks. As in the previous resource estimate, a preliminary open pit optimization algorithm was run on the estimated grade block model. Only mineralization contained within the preliminary pit shell has been included in the resource estimate.The base case mineral resource estimate is summarized in the following table at a cut-off grade of 3.0% Cg together with estimate sensitivities at 1.64% Cg and 5.0% Cg.
LOLA GRAPHITE PROJECT MINERAL RESOURCES AT A CUT-OFF GRADE OF 3.0% CG AND SENSITIVITIES AT 1.64%CG AND 5.0% CG CUT-OFF GRADES Base case mineral resources Cut-off grade Classification Tonnes Cg In situ Cg Cg % (Mt) (%) (t) 3% Measured 1.40 5.32 74,700 Indicated 10.79 5.58 602,200 Total ind. and meas. 12.20 5.55 676,900 Inferred 2.06 6.07 125,200 Sensitivities Cut-off grade Classification Tonnes Cg In situ Cg Cg % (Mt) (%) (t) 1.64% Measured 2.13 4.31 91,900 Indicated 17.00 4.39 746,400 Total ind. and meas. 19.14 4.38 838,400 Inferred 2.82 5.07 143,000 Cut-off grade Classification Tonnes Cg In situ Cg Cg % (Mt) (%) (t) 5% Measured 0.60 7.14 42,700 Indicated 5.02 7.46 374,800 Total ind. and meas. 5.62 7.43 417,500 Inferred 1.18 7.54 88,700
About Met-Chem/DRA
Met-Chem, a division of DRA Americas Inc., was originally established in 1969 as a consulting engineering company, headquartered in Montreal, and provides a wide range of technical and engineering services. Met-Chem is well recognized for its capabilities in mining, geology and mineral processing and has a talented team of engineering, technical and project management personnel with experience in North America, Latin America, Europe, West Africa and India. DRA is a multidisciplinary global engineering group that originated in South Africa and delivers mining, mineral processing, energy, water treatment and infrastructure services from concept to commissioning, as well as comprehensive operations and maintenance services for the mineral resources, water, agriculture and energy sectors. DRA has offices in Africa, Australia, Canada, China, India and the United States.
Qualified Person
Dr. Marc-Antoine Audet, P.Geo., Lead Geologist, SRG was responsible for estimating the mineral resources and has reviewed and approved the contents of this press release. Dr. Audet is a non-independent Qualified Person (“QP”) within the meaning of NI 43-101 – Standards of Disclosure for Mineral Projects of the Canadian Securities Administrators. Under subsection 5.3(1) paragraph (c), as the mineral resources have changed by less than 100% from the previous filing, an independent QP is not required for the filing of this mineral resource update.
ABOUT SRG
SRG is a Canadian-based company focused on developing the Lola graphite deposit and the Gogota nickel-cobalt deposit, both located in the Republic of Guinea, West Africa. SRG is committed to operating in a socially, environmentally and ethically responsible manner.
We seek Safe Harbor.
- Published in SRG Graphite
Tetra Bio-Pharma Takes on Fentanyl in Head to Head Trial for the Treatment of Breakthrough Pain
Momentum Public Relations
Press Release: June 18 2018
Tetra Bio-Pharma Inc., a leader in cannabinoid-based drug discovery and development (TSX VENTURE:TBP) (OTCQB:TBPMF), is pleased to announce that Santé Cannabis, the independently credentialed research organization they work with has finalized the clinical study protocol evaluation of PPP001, which will be the first time that cannabis is being compared to fentanyl in a clinical trial. The study protocol has received approval from the Independent Ethics Board (IRB Services) and was recently submitted for review to Health Canada. PPP001 will investigate cannabis as an alternative to fentanyl in the management of breakthrough pain. Santé Cannabis is a Quebec-based medical clinic specialized in clinical research and cannabis – based therapies.
Health Canada approved clinical trials completed by Tetra Bio-Pharma in 2017 and 2018 have led to a significantly improved understanding of the safety, pharmacokinetics and pharmacodynamics of PPP001 in the treatment of pain and suffering. The development of clinical research protocols to investigate the use of cannabis as an alternative to fentanyl followed Tetra’s meeting with the Therapeutic Products Directorate (TPD), Health Canada in early 2018. As a prescription drug, PPP001 will be eligible for insurance coverage.
The trial is designed to assess the time-to-relief in patients suffering from breakthrough pain. Based on its clinical data, Tetra believes that the pharmacodynamic properties of PPP001 may provide a novel alternative to fentanyl. In addition, the time-to-maximal plasma concentrations of THC suggests that PPP001 will provide rapid relief to the patient’s suffering.
“Patients suffering from breakthrough pain require fast relief. Overdosing from fentanyl may occur in patients that exceed the recommended dosage in the hope of obtaining a more rapid relief. The development of a THC-based alternative would help provide a safer option to these patients and help prevent overdosing on fentanyl,” said Dr. Antonio Vigano, an Attending Physician at the Supportive and Palliative Care Division, McGill University Health Centre, an Associate Professor in the department of oncology, McGill University and the Research Director of Santé Cannabis where he is a Principal Investigator in a Phase 3 clinical trial for pain associated with advanced cancer, in addition to a phase 2 trial for chronic pain. “PPP001 has the potential to become the long-awaited alternative to opioids for the management of breakthrough pain in cancer patients. Through this trial we are going to gather more evidence-based data on the safety, efficacy and ease of administration of inhaled cannabinoids as the complementary therapy of choice for cancer related pain.” said Dr. Vigano.
In Canada, the opioid crisis is serious and growing, and imposes devastating effects on families and communities. From January to September 2017, there were at least 2,923 apparent opioid-related deaths of which 92% were accidental. While males make up 76% of these fatalities, the highest percentage (28%) occurred among individuals between the ages of 30 and 39 years.i From January to September 2017, 72% of accidental apparent opioid-related deaths involved fentanyl or fentanyl analogues compared to 55% in 2016.
“Our rich cannabinoid-derived product pipeline has the potential to play a major role in opioid sparing, thus addressing a societal issue of critical proportion,“ said Guy Chamberland, Interim CEO and Chief of Scientific Affairs at Tetra Bio-Pharma. In addition, the R&D team is in discussions with Health Canada to take PPP001 into other therapeutic indications including fibromyalgia. In taking on new therapeutic indications for PPP001 we can, if successful, significantly increase the potential market as well shareholder value,” said Mr. Chamberland.
About Tetra Bio-Pharma
Tetra Bio-Pharma (TSX-V:TBP) (OTCQB:TBPMF) is a biopharmaceutical leader in cannabinoid-based drug discovery and development with a Health Canada approved, and FDA reviewed, clinical program aimed at bringing novel prescription drugs and treatments to patients and their healthcare providers. The Company has several subsidiaries engaged in the development of an advanced and growing pipeline of Bio Pharmaceuticals, Natural Health and Veterinary Products containing cannabis and other medicinal plant-based elements. With patients at the core of what we do, Tetra Bio-Pharma is focused on providing rigorous scientific validation and safety data required for inclusion into the existing bio pharma industry by regulators, physicians and insurance companies. For more information visit: www.tetrabiopharma.com
About Santé Cannabis
Established in Montreal, Quebec in 2014, Santé Cannabis is a Centre of Excellence in medical cannabis research, clinical practice and healthcare professional training. Since its inception, Santé Cannabis has provided medical assessment, education, monitoring and follow-up to 5000 patients referred by more than 2,000 Quebec physicians. Santé Cannabis operates within the guidelines for the authorization of medical cannabis as set out by the Collège des médecins du Québec. As an independently credentialed clinical trial research organization, and with unparalleled clinical experience supporting both patients and healthcare professionals, Santé Cannabis has established itself as a global leader in medical cannabis research. Santé Cannabis is currently conducting a Health Canada approved Phase 3 trial for PPP001 for advanced cancer patients suffering from uncontrolled pain and associated symptoms, as well as a Phase 2 trial for PPP005 investigating the use of oral capsules of cannabis oil for the treatment of chronic pain. For more information visit www.santecannabis.ca
More information at: www.tetrabiopharma.com
Source: Tetra Bio-Pharma
Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.
Forward-looking statements
Some statements in this release may contain forward-looking information. All statements, other than of historical fact, that address activities, events or developments that the Company believes, expects or anticipates will or may occur in the future (including, without limitation, statements regarding potential acquisitions and financings) are forward-looking statements. Forward-looking statements are generally identifiable by use of the words “may”, “will”, “should”, “continue”, “expect”, “anticipate”, “estimate”, “believe”, “intend”, “plan” or “project” or the negative of these words or other variations on these words or comparable terminology. Forward-looking statements are subject to a number of risks and uncertainties, many of which are beyond the Company’s ability to control or predict, that may cause the actual results of the Company to differ materially from those discussed in the forward-looking statements. Factors that could cause actual results or events to differ materially from current expectations include, among other things, without limitation, the inability of the Company to obtain sufficient financing to execute the Company’s business plan; competition; regulation and anticipated and unanticipated costs and delays, the success of the Company’s research and development strategies, the applicability of the discoveries made therein, the successful and timely completion and uncertainties related to the regulatory process, the timing of clinical trials, the timing and outcomes of regulatory or intellectual property decisions and other risks disclosed in the Company’s public disclosure record on file with the relevant securities regulatory authorities. Although the Company has attempted to identify important factors that could cause actual results or events to differ materially from those described in forward-looking statements, there may be other factors that cause results or events not to be as anticipated, estimated or intended. Readers should not place undue reliance on forward-looking statements. While no definitive documentation has yet been signed by the parties and there is no certainty that such documentation will be signed The forward-looking statements included in this news release are made as of the date of this news release and the Company does not undertake an obligation to publicly update such forward-looking statements to reflect new information, subsequent events or otherwise unless required by applicable securities legislation.
Investor Relations Contact:
Robert (Bob) Bechard
Executive Vice President, Corporate Development and Licensing
Tetra Bio-Pharma Inc.
514-817-2514
Media Contact:
energi PR
Carol Levine
514-288-8500 ext. 226
Stephanie Engel
416-425-9143 ext. 209
———————————-
i https://www.canada.ca/en/health-canada/services/substance-abuse/prescription-drug-abuse/opioids/apparent-opioid-related-deaths.html
- Published in Tetra Bio Pharma
Relevium Starts Production of Two Exclusive Formulations With Patented Provinal® Omega 7
Relevium Technologies Inc. (TSX.V:RLV) (OTCQB:RLLVF) and (Frankfurt:6BX) (the “Company” or “Relevium”), is pleased to announce it has put into production 920,000 soft-gels each of its Cardio-Metabolic Syndrome and Dry-Eye Syndrome formulations containing Provinal® Omega 7.
Highlights
- Relevium puts into production 920,000 soft gels using Provinal® is a patented ultra-purified Omega 7 fatty acid blend
- CardiaPro with Provinal® is shown to support cardio metabolic health by reducing insulin resistance, hepatic fat accumulation and acute and chronic inflammation
- VisionPro with Provinal® is also shown to improve the quality of tears and with its exclusive formulation, supports complete eye health
- First formulations with North American exclusivity for online sales through Amazon, Walmart and Native Website.
On December 6, 2017 the Company announced an exclusivity agreement with Tersus Life Sciences to formulate and distribute exclusive products with Provinal® Omega 7. The Company has put into production its first two formulations aimed at servicing two critical markets, Heart and Eye Health.
The two formulations will be marketed through BioGanix® Platinum and Bioganix® Gold labels throughout its online presence in its Native Website, Social Media, Amazon and Walmart and they are expected to be available for sale in September of this year.
Aurelio Useche CEO Stated: “The start of the production of these unique products represent a critical milestone for Relevium and its Bioganix® brand” Mr. Useche stated further: “We have been positively overwhelmed with the professionalism and excellence demonstrated by the team of scientists and formulators at Tersus Life Sciences and we are proud to be able to provide a superior and unique formulation with their patented Provinal® Omega 7 fish oil”.
About Provinal® Omega 7
Provinal® Omega 7 is a novel, patented and clinically-substantiated monounsaturated fatty-acid ingredient targeting the prevention and reversal of dyslipidemia, and cardio-metabolic disorders. Provinal® Omega 7 is a naturally-occurring highly purified monounsaturated fatty acid. Preclinical and clinical evidence has demonstrated a broad range of benefits bridging the treatment gap in highly prevalent disorders with special emphasis on lipid management.
Omega 7 (purified palmitoleic acid) oil of palmitate can potentially help in the fight against diabetes, metabolic syndrome, and atherosclerosis. In this 4-minute video, Dr. Michael F. Roizen, frequent contributor on the Dr. Oz show and Chairman of the Wellness Institute of The Cleveland Clinic, explores the beneficial effects of Provinal® on the management of atherosclerosis, its causes and consequences: heart disease, stroke, memory loss, impotence, and wrinkling.
Purified Omega 7 has been shown to decrease insulin resistance, decrease hepatic fat accumulation, and decrease acute and chronic inflammation – with no known side effects. More information can be found on the Tersus Life Sciences webpage at tersuslifesciences.com
About Relevium Technologies
Relevium is a TSXV-listed company focused on growth through the acquisition of businesses, products and/or technologies with a focus on e-commerce in the growing health and wellness sector. Relevium Technologies Inc. also holds patented intellectual property for the use of static magnetic fields for application on wearable devices.
Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.
Cautionary Note Regarding Forward-Looking Statements
This release includes certain statements and information that may constitute forward-looking information within the meaning of applicable Canadian securities laws. All statements in this news release, other than statements of historical facts, including statements regarding future estimates, plans, objectives, assumptions or expectations of future performance, including the timing and completion of the proposed acquisitions, are forward-looking statements and contain forward-looking information. Generally, forward- looking statements and information can be identified by the use of forward-looking terminology such as “intends” or “anticipates”, or variations of such words and phrases or statements that certain actions, events or results “may”, “could”, “should”, “would” or “occur”. Forward-looking statements are based on certain material assumptions and analysis made by the Company and the opinions and estimates of management as of the date of this press release, including the assumptions that the Company will obtain stock exchange approval of the Offering, the proposed acquisition will occur as anticipated, that the Company will raise sufficient funds, and that the Company will obtain all requisite approvals of the acquisition. These forward- looking statements are subject to known and unknown risks, uncertainties and other factors that may cause the actual results, level of activity, performance or achievements of the Company to be materially different from those expressed or implied by such forward-looking statements or forward-looking information. Important factors that may cause actual results to vary, include, without limitation, the risk that the proposed acquisitions may not occur as planned; the timing and receipt of requisite approvals and failure to raise sufficient funds under the Offering. Although management of the Company has attempted to identify important factors that could cause actual results to differ materially from those contained in forward-looking statements or forward-looking information, there may be other factors that cause results not to be as anticipated, estimated or intended.
There can be no assurance that such statements will prove to be accurate, as actual results and future events could differ materially from those anticipated in such statements. Accordingly, readers should not place undue reliance on forward- looking statements and forward-looking information. Readers are cautioned that reliance on such information may not be appropriate for other purposes. The Company does not undertake to update any forward-looking statement, forward-looking information or financial outlook that are incorporated by reference herein, except in accordance with applicable securities laws. We seek safe harbor.
On Behalf of the Board of Directors
RELEVIUM TECHNOLOGIES INC.
Aurelio Useche
President and CEO
For more information about this press release:
Tel: +1.888.528.8687
RELEVIUM TECHNOLOGIES INC
Email: investors@releviumcorp.com
Website: www.releviumtechnologies.com
Like us on Facebook
Follow us on Twitter
Follow us on LinkedIn
- Published in Relevium Technologies
SRG Graphite Inc. Announces Underwriters’ Full Exercise of Over-Allotment Option
Momentum Public Relations
Press Release: June 15 2018
SRG Graphite Inc. (TSXV:SRG) (“SRG” or the “Company”) is pleased to announce that the syndicate of underwriters co-led by National Bank Financial Inc. and TD Securities Inc. and including Macquarie Capital Markets Canada Ltd., Beacon Securities Limited and Clarksons Platou Securities AS (collectively, the “Underwriters”) for its May 2018 public offering (the “Offering”) of units of the Company (“Units”) has fully exercised the over-allotment option (the “Over-Allotment Option”) granted under the Offering to purchase 800,100 additional Units at a price of $1.50 per Unit (the “Offering Price”) for additional gross proceeds to the Company of $1,200,150. This results in aggregate gross proceeds of the Offering, including the exercise of the Over-Allotment Option on the date hereof, of $9,201,150. In addition to the previously announced concurrent private placement with Coris Capital S.A., this brings the aggregate gross proceeds of the raise to $11,201,150.
Each Unit issued under the Over-Allotment Option is comprised of one common share of the Company (a “Common Share”) and one Common Share purchase warrant of the Company (a “Warrant”). Each Warrant will entitle the holder thereof to acquire one additional Common Share at an exercise price of $2.30 per Common Share at any time for a period of 12 months from the closing of the Offering as press released on May 18, 2018.
The Company intends to use the proceeds from the Offering and the Over-Allotment Option for advancement of the Company’s Lola graphite project, including, in the near term, to further regional exploration and infill resource drilling and to progress towards a feasibility study; for continued exploration of its Gogota cobalt-nickel-scandium project; and for general working capital purposes.
The Offering was made pursuant to a short form prospectus dated May 11, 2018 (the “Prospectus”), filed in each of the Provinces of Canada and available on SEDAR at www.sedar.com.
This news release does not constitute an offer to sell or a solicitation of an offer to buy any of the securities in the United States. The securities have not been and will not be registered under the United States Securities Act of 1933, as amended (the “U.S. Securities Act”) or any state securities laws and may not be offered or sold within the United States or to U.S. Persons unless registered under the U.S. Securities Act and applicable state securities laws or an exemption from such registration is available.
ABOUT SRG
SRG is a Canadian-based company focused on developing the Lola graphite deposit and the Gogota cobalt-nickel-scandium deposit located in the Republic of Guinea, West Africa. SRG is committed to operating in a socially, environmentally and ethically responsible manner.
For additional information, please visit SRG’s website at www.srggraphite.com.
For more information contact: | |
Ugo Landry-Tolszczuk | Benoit La Salle, FCPA FCA |
Tel: +1 (514) 679-4196 | Tel: +1 (514) 951-4411 |
Email: ultolszczuk@srggraphite.com | Email: benoit.lasalle@srggraphite.com |
Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.
Forward-Looking Statements
This press release contains “forward-looking information” within the meaning of Canadian securities legislation. All information contained herein that is not clearly historical in nature may constitute forward-looking information. Generally, such forward-looking information can be identified by the use of forward-looking terminology such as “reduce”, “suggest”, “opportunity”, “demonstrate”, or variations of such words and phrases or state that certain actions, events or results “may”, “could”, “would” or “might” occur. Forward-looking information is subject to known and unknown risks, uncertainties and other factors that may cause the actual results, level of activity, performance or achievements of the Company to be materially different from those expressed or implied by such forward-looking information, including but not limited to: (i) the Company’s use of proceeds of the Offering and the Over-Allotment Option may differ from those indicated; (ii) volatile stock price; (iii) the general global markets and economic conditions; (iv) the possibility of write-downs and impairments; (v) the risk associated with exploration, development and operations of mineral deposits; (vi) the risk associated with establishing title to mineral properties and assets; (vii) fluctuations in commodity prices and other risks and factors described or referred to in the sections entitled “Risk Factors” in the Annual Information Form of the Company and the Prospectus available at www.sedar.com, all of which should be reviewed in conjunction with the information found in this news release.
Forward-looking information is based on assumptions management believes to be reasonable at the time such statements are made, including but not limited to, continued exploration activities and no material adverse change in mineral prices. Although the Company has attempted to identify important factors that could cause actual results to differ materially from those contained in the forward-looking information, there may be other factors that cause results not to be as anticipated, estimated or intended. There can be no assurance that such forward-looking information will prove to be accurate, as actual results and future events could differ materially from those anticipated in such forward-looking information. Such forward-looking information has been provided for the purpose of assisting investors in understanding the Company’s business, operations and exploration plans and may not be appropriate for other purposes. Accordingly, readers should not place undue reliance on forward-looking information. Forward-looking information is given as of the date of this press release, and the Company does not undertake to update such forward-looking information except in accordance with applicable securities laws.
- Published in SRG Graphite, Uncategorized